{"id":37318,"date":"2026-05-09T10:44:00","date_gmt":"2026-05-09T14:44:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=37318"},"modified":"2026-03-10T21:57:15","modified_gmt":"2026-03-11T01:57:15","slug":"south-american-drug-patents-the-definitive-country-by-country-breakdown","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/south-american-drug-patents-the-definitive-country-by-country-breakdown\/","title":{"rendered":"South American Drug Patents: The Definitive Country-by-Country Breakdown"},"content":{"rendered":"\n

Patent Terms, Data Exclusivity, Compulsory Licensing, and Generic Entry Across 11 Markets<\/em><\/p>\n\n\n\n

Why South America Is the World’s Most Contested Patent Battleground<\/strong><\/h1>\n\n\n\n
\"\"<\/figure>\n\n\n\n

South America is home to 440 million people, five upper-middle-income economies, and some of the most aggressive pharmaceutical patent policies on earth. Brazil alone has issued compulsory licenses on antiretroviral drugs that changed global pricing norms. Argentina has maintained patentability examination guidelines so strict that multinational pharmaceutical companies routinely classify the country alongside India as a jurisdiction requiring a separate IP strategy. Colombia declared imatinib a matter of public interest and forced Novartis into a price negotiation that resonated across Latin America. These are not peripheral markets. They are where pharmaceutical patent law gets road-tested under political and public health pressure that high-income countries rarely generate.<\/p>\n\n\n\n

For pharmaceutical executives, patent attorneys, generic manufacturers, health economists, and investors, understanding exactly how long a drug patent lasts in each South American country is not an academic exercise. It determines when a generic competitor can legally enter the market, whether data exclusivity protection runs concurrently or independently with patent protection, how much a compulsory license threat changes the negotiating dynamic with governments, and whether a product acquisition target in Sao Paulo has the same exclusivity runway as an equivalent asset in Bogota or Lima.<\/p>\n\n\n\n

The answer to “how long do drug patents last in South America” is not a single number. It is a matrix of 11 different national systems, three regional frameworks, a set of bilateral free trade agreement obligations, and administrative realities that can extend effective patent pendency far beyond the statutory 20-year baseline. This analysis unpacks each layer.<\/p>\n\n\n\n

Patent data aggregation platforms like DrugPatentWatch have expanded their coverage of Latin American markets in recent years, recognizing that the exclusivity cliffs and generic entry timelines in South America increasingly affect the global revenue models of both innovator and generic pharmaceutical companies [1]. This article draws on that data alongside primary legal sources, patent office statistics, and reported litigation outcomes to give you a current, actionable picture of the regional landscape.<\/p>\n\n\n\n

The Foundation: TRIPS and How South America Signed On<\/strong><\/h1>\n\n\n\n

What TRIPS Actually Requires<\/strong><\/h2>\n\n\n\n

The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which entered into force in 1995 as part of the WTO agreements, set the global minimum standard for pharmaceutical patent protection. Under Article 28, patent holders receive the right to prevent third parties from making, using, offering for sale, selling, or importing the patented product. Under Article 33, patent terms must be at least 20 years from the filing date. TRIPS does not require patent term extensions, supplementary protection certificates, data exclusivity beyond a limited provision, or patent linkage between drug approval and patent status. Those additions came through bilateral pressure.<\/p>\n\n\n\n

Every South American country is a WTO member and is therefore bound by TRIPS. The developing-country transition periods that allowed some nations to delay pharmaceutical patent implementation expired in 2000 for most South American countries, with least-developed countries receiving longer transitions that are not applicable to any major South American market. As of 2024, all 11 South American countries maintain pharmaceutical patent systems nominally compliant with TRIPS, though their actual implementation differs substantially in patentability standards, examination procedures, and enforcement mechanisms.<\/p>\n\n\n\n

The critical TRIPS flexibility that South American countries have relied on most heavily is Article 31, which permits compulsory licensing under specified conditions, including national emergencies, extreme urgency, and public non-commercial use. The Doha Declaration on TRIPS and Public Health, adopted in 2001, explicitly confirmed that TRIPS “does not and should not prevent Members from taking measures to protect public health” and affirmed the right to compulsory licensing. Brazil and Ecuador cited the Doha Declaration directly when issuing their compulsory licenses on antiretroviral drugs. Colombia relied on it implicitly in its 2016 imatinib decision [2].<\/p>\n\n\n\n

The TRIPS-Plus Pressure From Bilateral Free Trade Agreements<\/strong><\/h2>\n\n\n\n

While TRIPS sets a floor, bilateral free trade agreements (FTAs) negotiated by the United States and the European Union have pushed several South American countries to adopt protections well above that floor. These TRIPS-plus obligations include patent linkage (connecting drug regulatory approval to patent status), data exclusivity (protecting undisclosed clinical trial data from use by generic applicants for defined periods), and in some cases patent term restoration to compensate for regulatory delays.<\/p>\n\n\n\n

The FTAs most relevant to South America are the U.S.-Colombia Trade Promotion Agreement, which entered into force in 2012, and the U.S.-Peru Trade Promotion Agreement, which entered into force in 2009. Both agreements require data exclusivity for at least five years for new pharmaceutical products and for at least three years for new uses of known active ingredients. Both require some form of patent linkage, meaning regulatory authorities must either notify patent holders or take patent status into account when granting marketing approvals. Neither agreement goes as far as requiring patent term restoration, but Peru negotiated a side letter that created a pathway for restoration claims that has not been fully implemented.<\/p>\n\n\n\n

The U.S.-Colombia and U.S.-Peru FTAs in Practice<\/strong><\/h3>\n\n\n\n

Colombia’s implementation of its FTA patent obligations has been contentious. Decree 729 of 2012 established a patent linkage system under which the National Food and Drug Surveillance Institute (INVIMA) must notify patent holders when a generic application is filed for a patented product. This notification mechanism does not create an automatic stay of generic approval, but it gives patent holders information necessary to seek injunctions through the courts. The practical effect has been to create a slower generic entry process without fully eliminating the ability of health authorities to approve generics on public health grounds.<\/p>\n\n\n\n

In Peru, the INDECOPI patent office has grappled with implementing data exclusivity under the FTA while maintaining the country’s ability to use compulsory licensing and other public health flexibilities. Peru’s data exclusivity regime protects clinical trial data for five years from first marketing authorization, but only for products that were not previously approved in Peru. Generic companies have argued that this creates a shorter effective protection period than U.S. or European data exclusivity, because Peru’s regulatory process is slower and the five-year clock often starts later than in high-income markets.<\/p>\n\n\n\n

The Andean Community (CAN) as the Regional Baseline<\/strong><\/h3>\n\n\n\n

For four South American countries — Colombia, Peru, Ecuador, and Bolivia — the Andean Community (Comunidad Andina, or CAN) provides a regional intellectual property framework through Decision 486, which was adopted in 2000 and serves as the primary IP law for member states. Decision 486 sets the 20-year patent term from filing, establishes patentability requirements (novelty, inventive step, and industrial applicability), and contains provisions on compulsory licensing and exceptions to patent rights.<\/p>\n\n\n\n

Decision 486 is notable for what it excludes. Under Article 20, new uses of known active ingredients are not patentable. New forms of known substances, including new salts, esters, ethers, polymorphs, metabolites, and combinations, are not patentable unless they differ significantly in efficacy. This provision directly counteracts the “evergreening” strategies commonly used by brand pharmaceutical companies in high-income markets to extend effective patent protection beyond the original compound’s exclusivity. CAN countries have therefore maintained a stronger statutory barrier to evergreening than Brazil or Argentina, though enforcement varies considerably in practice.<\/p>\n\n\n\n

Brazil: The Giant With Its Own Rules<\/strong><\/h1>\n\n\n\n

Basic Patent Term and the INPI System<\/strong><\/h2>\n\n\n\n

Brazil is the largest pharmaceutical market in South America and the eighth-largest in the world by revenue, generating approximately $29 billion in annual drug sales [3]. Its patent system is governed by Law No. 9.279\/1996, the Industrial Property Law, which sets the basic patent term at 20 years from the filing date, consistent with TRIPS. For utility models, the term is 15 years from filing. Brazil does not have a patent term extension system equivalent to the U.S. PTE or European SPC, meaning the 20-year term from filing is, in principle, the maximum available protection for any pharmaceutical patent.<\/p>\n\n\n\n

The critical practical issue in Brazil is the examination backlog at the Instituto Nacional da Propriedade Industrial (INPI-BR). Pharmaceutical patent applications in Brazil historically took between 7 and 11 years from filing to examination, meaning that a patent filed in 2010 might receive its grant decision only in 2018 or later. This backlog created a perverse outcome: pharmaceutical companies received their patents late in the 20-year term, reducing their effective commercial exclusivity period relative to countries with faster examination timelines.<\/p>\n\n\n\n

To address this, Brazil’s INPI historically adopted a “minimum term” policy: under Sole Paragraph of Article 40 of the Industrial Property Law, if a patent was not examined within 10 years of filing, the patentee received at least 10 years of protection from the grant date, even if that pushed the expiry beyond 20 years from filing. This provision effectively created a de facto patent term extension for pharmaceutical patents caught in the backlog, generating significant revenue for brand drug companies at the expense of generic entry timing.<\/p>\n\n\n\n

The 2021 Supreme Court Decision and Its Aftermath<\/strong><\/h2>\n\n\n\n

In May 2021, Brazil’s Supreme Federal Tribunal (STF) declared the minimum-term provision of Article 40 unconstitutional in a decision that affected all pharmaceutical, agrochemical, and input patents granted under the minimum-term rule. The STF’s ruling in Direct Action of Unconstitutionality (ADI) 5529 held that the minimum-term provision conflicted with the constitutional principle of free competition by allowing patent terms to exceed the 20 years from filing mandated by TRIPS and the Brazilian constitution’s IP framework [4].<\/p>\n\n\n\n

The immediate commercial effect was substantial. INPI identified approximately 2,700 pharmaceutical patents that had received minimum-term extensions. These patents, many covering blockbuster drugs marketed by companies including AbbVie, AstraZeneca, Bayer, and Pfizer, faced immediate expiry rather than the extended terms they had counted on. Generic manufacturers in Brazil, including EMS, Eurofarma, and Medley, moved quickly to seek marketing approvals for generic versions of affected products. For brand companies, the STF decision eliminated billions of reais in projected protected revenues.<\/p>\n\n\n\n

The Brazilian government negotiated a transitional period before the decision took full effect, and some companies challenged the retroactive application to patents already granted. INPI subsequently revised its examination procedures to process applications more quickly, reducing the backlog that had created the minimum-term problem in the first place. As of 2024, INPI’s average examination time for pharmaceutical applications has dropped to approximately 5 to 7 years, still longer than U.S. or European timelines but significantly improved from the peak of the backlog period.<\/p>\n\n\n\n

Patent Linkage: What Brazil Rejected<\/strong><\/h2>\n\n\n\n

Brazil has consistently refused to implement patent linkage. Under the Brazilian regulatory system, the National Health Surveillance Agency (ANVISA) evaluates drug applications on public health criteria without any formal obligation to check patent status or notify patent holders. ANVISA does have a historical prior consent mechanism under Decree 4,830 of 2003, under which ANVISA participated in reviewing pharmaceutical patent applications with public health implications. However, this mechanism was a form of patent quality review, not patent linkage, and it was repealed by Law 13.123\/2015.<\/p>\n\n\n\n

The absence of patent linkage means that generic companies in Brazil can obtain regulatory approval for a product while patent litigation is pending. They cannot legally sell the product if a valid patent covers it, but the regulatory pathway is not blocked. This creates a situation where generic companies frequently have approved products ready for market entry the moment a patent expires or is invalidated, dramatically shortening the post-expiry transition period compared to markets where regulatory approval itself is delayed by patent status. The practical impact is that Brazilian patent cliffs are sharper than those in Colombia or Peru, because the generic product often exists and is pre-approved before day one of legal market entry.<\/p>\n\n\n\n

Data Exclusivity in Brazil: The 10-Year Debate<\/strong><\/h3>\n\n\n\n

Brazil’s data exclusivity system has been the subject of political controversy for over two decades. Decree 3.201\/1999, as amended by Decree 4.830\/2003, provides 10 years of data protection for pharmaceutical products containing new active substances. This period runs from the first marketing authorization of the product in Brazil, not from a foreign regulatory approval. The 10-year term is longer than the 5-year standard required by TRIPS-plus FTAs, but Brazil is not party to any FTA that would enforce a shorter term.<\/p>\n\n\n\n

The practical application of Brazilian data exclusivity is limited by two factors. First, the 10-year period runs from Brazilian approval, and Brazil’s regulatory approval timeline is typically 2 to 4 years longer than U.S. or European approval for the same product. This means that by the time data exclusivity begins in Brazil, competing clinical data generated independently elsewhere may already exist, reducing the exclusivity’s commercial significance. Second, ANVISA has interpreted the data exclusivity provisions narrowly, requiring that the data being protected was submitted to ANVISA specifically, not simply that the product was approved elsewhere.<\/p>\n\n\n\n

Compulsory Licensing: Brazil’s Most-Used Weapon<\/strong><\/h3>\n\n\n\n

Brazil has issued compulsory licenses on pharmaceutical patents more frequently than any other South American country, and its 2007 compulsory license on efavirenz remains the most cited example of a major economy exercising this TRIPS flexibility for a patented drug used in national disease control.<\/p>\n\n\n\n

Efavirenz and the 2007 Precedent<\/strong><\/h4>\n\n\n\n

Efavirenz (marketed as Stocrin by Merck) was the cornerstone of Brazil’s national HIV\/AIDS treatment program. Brazil had negotiated price reductions with Merck multiple times throughout the early 2000s, but the price remained substantially higher than the generic versions produced in India and Thailand. In May 2007, President Lula da Silva signed a presidential decree declaring efavirenz of public interest and authorizing ANVISA to import generic efavirenz from Indian manufacturer Ranbaxy, bypassing Merck’s patent.<\/p>\n\n\n\n

Merck’s patent on efavirenz had approximately 5 years of remaining protection at the time. The Brazilian government estimated that the compulsory license would save approximately $30 million annually in its HIV\/AIDS treatment program, representing the cost difference between Merck’s price of $1.57 per tablet and India’s generic price of approximately $0.45 per tablet [5]. Merck ultimately negotiated a further price reduction that fell between these figures, and the compulsory license became a template that Ecuador, Bolivia, and other South American governments studied and adapted.<\/p>\n\n\n\n

The broader significance of the efavirenz decision for pharmaceutical patent strategy in South America cannot be understated. It established that Brazil would exercise its TRIPS Article 31 rights in practice, not merely as a theoretical negotiating lever. Pharmaceutical companies pricing new drugs in Brazil now routinely model the compulsory license risk as a real financial scenario, not a remote contingency. The threat alone has been sufficient to produce price concessions in subsequent negotiations over sofosbuvir (hepatitis C treatment, Gilead), bedaquiline (tuberculosis, Johnson & Johnson), and other high-cost therapies.<\/p>\n\n\n\n

The Pipeline Patent System and Retroactivity<\/strong><\/h2>\n\n\n\n

Between 1997 and 2000, Brazil operated a “pipeline” patent system under Articles 230-232 of the 1996 Industrial Property Law. This system allowed pharmaceutical products and processes that had not previously been patented in Brazil to receive patent protection retroactively, without examination of inventive step or novelty, based solely on the remaining term of a foreign patent for the same product. The pipeline system was intended as a transitional mechanism to bring Brazil into TRIPS compliance.<\/p>\n\n\n\n

The pipeline system granted patents on hundreds of pharmaceutical products, including well-known drugs whose Brazilian patents would not have been granted under normal examination standards. INPI estimates that approximately 1,182 pharmaceutical pipeline patents were granted between 1997 and 2000. Many of these patents faced validity challenges in Brazilian courts during their terms, with mixed results. Critics, including Brazilian academic researchers like Carlos Correa at ICTSD, argued that the pipeline system violated TRIPS by granting retroactive protection without a TRIPS-compliant examination, while patent holders argued it was a legitimate transitional measure [6].<\/p>\n\n\n\n

The pipeline patents have now largely expired given their 1990s filing dates. But they left behind a significant body of patent litigation case law and a Brazilian legal tradition of scrutinizing pharmaceutical patent validity more closely than many other jurisdictions. Brazilian federal courts regularly invalidate pharmaceutical patents on grounds of insufficient inventive step, a standard that courts apply with reference to a “person skilled in the art” who is assumed to have knowledge of prior art in the specific therapeutic area.<\/p>\n\n\n\n

Argentina: The 2012 Guidelines and the Never-Ending Reform Debate<\/strong><\/h1>\n\n\n\n

Patent Term and the INPI-AR Backlog Problem<\/strong><\/h2>\n\n\n\n

Argentina’s patent system is governed by Law 24.481 of 1995, as amended by Law 24.572 of 1995 and subsequent regulations. The basic pharmaceutical patent term is 20 years from the filing date, consistent with TRIPS. Argentina does not have a patent term extension system or a supplementary protection certificate mechanism. The effective commercial exclusivity period is therefore determined by the difference between the filing date and the date by which INPI-AR completes examination, which in the pharmaceutical sector has historically been one of the slowest in the world.<\/p>\n\n\n\n

The Argentine INPI-AR backlog for pharmaceutical patents is severe. As of the most recent available data, the pharmaceutical examination queue at INPI-AR contains more than 60,000 pending applications, with average examination times in the pharmaceutical sector exceeding 8 to 12 years from filing [7]. This backlog is the result of systematic underfunding of the patent office, inadequate examiner staffing, and the complexity of pharmaceutical patent claims that require specific scientific expertise to evaluate.<\/p>\n\n\n\n

The backlog creates a paradox for both innovators and generic manufacturers. For brand drug companies, filing a pharmaceutical patent in Argentina early in the drug development process means the patent will be granted late in the 20-year term, potentially leaving only 8 to 12 years of effective commercial exclusivity. For generic manufacturers, the pending patent represents a cloud over the product: they know the patent exists and may be granted, but they do not know when or in what form. This uncertainty makes generic entry planning in Argentina more complex than in any other major South American market.<\/p>\n\n\n\n

Argentina’s Patentability Standards: The 2012 Guidelines<\/strong><\/h2>\n\n\n\n

In 2012, Argentina’s INPI-AR, in coordination with the National Administration of Medicines, Food and Medical Technology (ANMAT) and the Health Ministry, issued Joint Resolution 118\/2012, which established specific patentability examination guidelines for pharmaceutical products. These guidelines, commonly known as the “2012 Guidelines” or “Resolution 118,” set rigorous standards for what constitutes a patentable pharmaceutical invention, specifically targeting strategies that multinational companies use to extend effective patent protection beyond the original compound.<\/p>\n\n\n\n

Under the 2012 Guidelines, patents on new polymorphs (different crystalline forms of the same molecule) are not granted unless a significant, unexpected improvement in therapeutic efficacy is demonstrated. New salts, esters, ethers, and other derivatives of known active ingredients are not patentable unless they demonstrate significantly different properties from the parent compound. New formulations, dosage forms, and dosing schedules are not patentable as new inventions. New therapeutic uses of known compounds are not patentable [8].<\/p>\n\n\n\n

The guidelines drew immediate criticism from the Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA), both of which argued that the standards exceeded what TRIPS permitted countries to impose and discriminated against foreign patent applicants. The U.S. Trade Representative placed Argentina on its Special 301 “Watch List” based in part on the 2012 Guidelines and maintained this designation through multiple subsequent annual reviews.<\/p>\n\n\n\n

Argentina’s government and a broad coalition of public health organizations defended the guidelines as legitimate use of TRIPS flexibilities. The Inter-American Commission on Human Rights cited the guidelines approvingly in a 2014 report on access to medicines, noting that patent systems should balance innovation incentives with public health needs. The guidelines remain in force as of 2024, substantially unchanged, and have become the template that other South American countries and global health advocates have referenced when designing their own patentability standards.<\/p>\n\n\n\n

Data Exclusivity: What Argentina Refuses to Grant<\/strong><\/h2>\n\n\n\n

Argentina has not enacted a comprehensive data exclusivity framework for pharmaceutical products. While Decree 150\/1992 contains provisions on the confidentiality of clinical trial data submitted to ANMAT, these provisions protect against unfair commercial use of the data rather than granting a period of exclusive use. Generic applicants in Argentina can rely on the published safety and efficacy data of the reference product or conduct their own bioequivalence studies without needing to wait for any exclusivity period to expire [9].<\/p>\n\n\n\n

This position has been a persistent source of friction with the United States. The U.S.-Argentina Trade and Investment Framework Agreement, signed in 1991, contemplated eventual negotiations on IP standards, but no bilateral FTA has been concluded. Argentina declined to enter trade negotiations with the U.S. that would have required TRIPS-plus commitments, including data exclusivity. Successive Argentine governments from both the Peronist and center-right political traditions have maintained this position, reflecting a broad national consensus that data exclusivity primarily benefits foreign pharmaceutical companies at the expense of Argentine patients and the public health budget.<\/p>\n\n\n\n

The practical consequence for pharmaceutical companies operating in Argentina is that the effective exclusivity period for a new drug is determined entirely by patent protection, with no data exclusivity backstop. When the relevant patents expire or are invalidated, generic manufacturers can enter the market without any additional waiting period. For drugs that relied on data exclusivity in other markets to extend protection beyond patent expiry, the Argentine market offers less protection.<\/p>\n\n\n\n

The Evergreening Battle in Argentine Courts<\/strong><\/h3>\n\n\n\n

Argentine courts have been consistent in applying the 2012 Guidelines and the pre-existing restrictive patentability standards set out in earlier INPI-AR examination criteria. In a series of decisions between 2015 and 2022, Argentine courts invalidated or refused patents on polymorphic forms, new salt forms, and method-of-use claims for established active ingredients, citing lack of inventive step under the Argentinian standard [10].<\/p>\n\n\n\n

One particularly significant case involved a major oncology product whose patent holder sought to extend protection through a new polymorph patent. INPI-AR refused the application on the grounds that the polymorph did not demonstrate improved therapeutic efficacy relative to the base compound. The patent holder appealed through the Argentine federal courts and ultimately lost, with the court explicitly citing the 2012 Guidelines as the governing patentability standard. Generic manufacturers subsequently entered the Argentine market for that product approximately 3 years earlier than they entered comparable markets in Brazil or Colombia, where the polymorph patent survived examination.<\/p>\n\n\n\n

Colombia: TRIPS-Plus Under Pressure<\/strong><\/h1>\n\n\n\n

The CAN Decision 486 Framework and Colombian Implementation<\/strong><\/h2>\n\n\n\n

Colombia’s pharmaceutical patent system operates at two levels: the Andean Community framework under Decision 486, and national Colombian law, primarily Law 1648 of 2013 on pharmaceutical policy and the relevant decrees implementing the U.S.-Colombia FTA. Decision 486 governs patentability standards, including the exclusion of new uses and new forms of known compounds from patent eligibility. Colombian national law adds the data exclusivity, patent linkage, and regulatory authority notification requirements introduced by the FTA.<\/p>\n\n\n\n

The Colombian patent term is 20 years from filing, consistent with CAN Decision 486 and TRIPS. The Superintendencia de Industria y Comercio (SIC) is the national patent authority. SIC examination of pharmaceutical applications takes approximately 4 to 6 years from filing, making Colombia one of the faster Latin American patent offices, though still substantially slower than U.S. or European equivalents. The SIC has developed specialized pharmaceutical examination guidelines that reflect both CAN Decision 486 standards and the FTA-influenced national law provisions.<\/p>\n\n\n\n

Linkage Regulation and Decree 729<\/strong><\/h2>\n\n\n\n

Colombia’s patent linkage system, established by Decree 729 of 2012 implementing the U.S.-Colombia FTA, requires INVIMA to notify the SIC and relevant patent holders when it receives a pharmaceutical marketing authorization application for a product that may be covered by a listed patent. This notification mechanism does not automatically block generic approval, but it creates a structured communication channel that patent holders can use to seek judicial injunctions against the generic approval process.<\/p>\n\n\n\n

In practice, Decree 729 has been modified by subsequent court decisions and ministerial interpretations. Colombian courts have held that the linkage mechanism cannot be used to block generic approvals where the patent in question is of doubtful validity or where public health concerns are present. The Constitutional Court of Colombia has been particularly active in scrutinizing patent linkage applications that would restrict access to essential medicines, citing the right to health enshrined in the Colombian constitution as a counterweight to patent exclusivity.<\/p>\n\n\n\n

Compulsory Licensing After the Imatinib Crisis<\/strong><\/h2>\n\n\n\n

Colombia’s 2016 declaration of imatinib (Novartis’s Gleevec) as a public interest medicine marked the first time a Latin American government had threatened a compulsory license on a cancer drug rather than an antiretroviral or antibiotic. The Minister of Health issued Resolution 2475 in May 2016 declaring that imatinib met the criteria for a public interest declaration under Colombian law, which was a precursor step to a formal compulsory license [11].<\/p>\n\n\n\n

Novartis responded by challenging the declaration in Colombian courts, arguing that the procedural requirements for a public interest declaration had not been met and that the international trade obligations Colombia had assumed under its FTA precluded compulsory licensing on grounds that did not meet the narrow definitions in Article 31 of TRIPS. The Colombian Council of State suspended the declaration pending review. The case was ultimately unresolved in traditional terms: Novartis offered price reductions sufficient to satisfy the Colombian government’s cost-effectiveness requirements, and the compulsory license was not formally issued.<\/p>\n\n\n\n

The imatinib episode established a pattern that has been repeated in Colombia for several subsequent high-cost drugs. In 2016, Colombia also threatened a compulsory license on sofosbuvir (Gilead’s hepatitis C treatment Sovaldi), which generated price reductions. In 2022, similar pressure was applied to bedaquiline (Johnson & Johnson’s tuberculosis drug). In each case, the credibility of the compulsory license threat depended on Colombia’s demonstrated willingness to issue one. The imatinib near-miss gave that threat significant weight.<\/p>\n\n\n\n

The Role of the SIC in Patent Quality<\/strong><\/h3>\n\n\n\n

The SIC has invested significantly in pharmaceutical patent examination quality, developing a specialized pharmaceutical unit and implementing examination guidelines that align with the CAN Decision 486 prohibition on evergreening patents. The SIC regularly sends examiners to training programs on pharmaceutical patent examination at WIPO and in collaboration with the European Patent Office. The result is a patent examination quality that, while slower than ideal, produces more consistent and legally defensible decisions than INPI-AR or INPI-BR at their most backlogged periods.<\/p>\n\n\n\n

The SIC also maintains a public database of pharmaceutical patents, which interfaces with INVIMA’s drug registration database to create a patent-product mapping that is used both for linkage notification purposes and for public monitoring of pharmaceutical exclusivity. This database, while not as comprehensive as the U.S. Orange Book, has become a reference point for generic manufacturers, health authorities, and academics studying the Colombian pharmaceutical market. Generic companies use it alongside international databases to plan market entry strategies for Colombia.<\/p>\n\n\n\n

Peru: FTA Commitments vs. Public Health Pressure<\/strong><\/h1>\n\n\n\n

Patent Term and the INDECOPI Process<\/strong><\/h2>\n\n\n\n

Peru’s pharmaceutical patent system is governed by CAN Decision 486 for patentability standards and by the national Intellectual Property Law (Legislative Decree 1075 of 2008) for procedural matters. The basic pharmaceutical patent term is 20 years from filing. INDECOPI (Instituto Nacional de Defensa de la Competencia y de la Proteccion de la Propiedad Intelectual) handles patent examination with an average time of 4 to 7 years for pharmaceutical applications. Peru is a mid-tier performer on examination speed in the South American context.<\/p>\n\n\n\n

Peru was the first South American country to negotiate a comprehensive FTA with the United States, and the implementation of that agreement in 2009 introduced TRIPS-plus obligations that changed the pharmaceutical patent landscape significantly. The key additions were a data exclusivity framework for at least five years, a patent linkage mechanism under which DIGEMID (Peru’s drug regulatory authority) must take into account patent status when granting marketing authorizations, and a side letter addressing the possibility of patent term restoration for regulatory delays.<\/p>\n\n\n\n

Data Exclusivity Under the US-Peru FTA<\/strong><\/h2>\n\n\n\n

Peru’s data exclusivity framework, implemented through Decree 1092 of 2008 and subsequent DIGEMID regulations, provides five years of protection for undisclosed clinical trial data submitted in connection with a new pharmaceutical product’s marketing authorization. The five-year period runs from the date of first marketing authorization in Peru, not from foreign approval. The framework applies to new molecular entities — compounds with no prior regulatory approval anywhere in the world — and separately provides three years of data exclusivity for new clinical uses of previously approved compounds.<\/p>\n\n\n\n

The practical application of Peru’s data exclusivity has generated several disputes. Generic manufacturers have challenged whether data exclusivity applies when they conduct independent bioequivalence studies rather than relying on the innovator’s clinical data. DIGEMID has generally held that data exclusivity does not prevent generic approvals based on independently generated data, only approvals that rely directly on or reference the innovator’s protected data package. This interpretation aligns with a narrow reading of TRIPS Article 39.3 and limits the exclusivity’s commercial scope significantly.<\/p>\n\n\n\n

The data exclusivity period also runs concurrently with patent protection in most cases, rather than extending beyond it. Since most new molecular entities have active patent protection for well beyond five years from their Peruvian approval date, the data exclusivity rarely adds incremental protection that is not already provided by the patent. Where it matters most is for drugs that are unpatented in Peru (because the company chose not to file a Peruvian patent application) but whose regulatory data the company still wants to protect from reference by generic applicants.<\/p>\n\n\n\n

Patent Linkage Implementation and Its Limits<\/strong><\/h2>\n\n\n\n

Peru’s patent linkage system under the FTA requires DIGEMID to consult the INDECOPI patent register when processing generic drug applications and to notify patent holders of pending generic approvals for products they believe are covered by a valid Peruvian patent. Unlike the U.S. Orange Book linkage system, Peruvian linkage does not create an automatic stay of generic approval. Patent holders who receive a notification must seek a judicial injunction if they want to prevent or delay the generic approval, and Peruvian courts have applied varying standards to whether such injunctions should be granted.<\/p>\n\n\n\n

Several Peruvian court decisions between 2015 and 2022 have clarified that patent linkage notification does not give the patent holder a right to delay generic approval absent a specific judicial order, and that courts will not automatically grant injunctions against generic approvals without evidence of irreparable harm beyond the commercial loss from competition itself. This judicial interpretation limits the practical effect of linkage to an information mechanism rather than a formal barrier to generic entry, which is consistent with the minimum FTA obligation but substantially less restrictive than the U.S. system.<\/p>\n\n\n\n

Patent Term Restoration: The Unfulfilled Promise<\/strong><\/h3>\n\n\n\n

The side letter to the U.S.-Peru FTA contemplated that Peru would create a mechanism for patent term restoration to compensate for delays in patent examination and drug regulatory approval. No such mechanism has been implemented as of 2024. INDECOPI completed an internal study of the feasibility of a term restoration system in 2019 but did not proceed to draft implementing legislation. The primary obstacles were the INDECOPI backlog (which would make restoration calculations complex and potentially very large), the absence of political constituency for a measure that would primarily benefit foreign pharmaceutical companies, and the potential incompatibility with CAN Decision 486, which does not contemplate patent term restoration.<\/p>\n\n\n\n

The FTA’s side letter commits Peru to using “best efforts” to implement term restoration, a formulation that falls short of a mandatory obligation. U.S. pharmaceutical industry associations have periodically raised the non-implementation of term restoration in trade reviews under the Special 301 process, but Peru has not faced formal dispute settlement proceedings on the issue. The effective result is that Peru’s pharmaceutical patents last 20 years from filing, with no extension mechanism, making it identical to Argentina on this metric despite their very different patentability and data exclusivity frameworks.<\/p>\n\n\n\n

Chile: The Modernized IP Framework<\/strong><\/h1>\n\n\n\n

IP Law 19.039 and Recent Amendments<\/strong><\/h2>\n\n\n\n

Chile’s pharmaceutical patent system is governed by Law 19.039 of 1991 on Industrial Property, as significantly amended by Law 19.996 of 2005 and Law 20.160 of 2007 implementing its FTA commitments, and most recently by Law 21.335 of 2021. The basic patent term is 20 years from filing, with no extension mechanism. Chile is not a CAN member, meaning it does not have the CAN Decision 486 framework and instead applies its own patentability standards, which are generally aligned with TRIPS but have been shaped by FTA obligations toward TRIPS-plus in specific areas.<\/p>\n\n\n\n

Chile’s patent examination office, INAPI (Instituto Nacional de Propiedad Industrial), is among the more efficient in South America, with pharmaceutical application examination times of approximately 3 to 5 years from filing. INAPI has invested in examiner training and in examination guidelines that provide clearer criteria for patentability assessments, reducing appeal rates and improving predictability for both applicants and generic manufacturers.<\/p>\n\n\n\n

The 2021 amendment (Law 21.335) updated the data exclusivity framework and clarified several procedural aspects of the patent linkage system. Notably, the amendments maintained the five-year data exclusivity period for new chemical entities and extended the period under which generic applicants must provide certification of patent status to ANAMED (Agencia Nacional de Medicamentos) during the drug approval process. The 2021 reforms were broadly neutral between innovators and generic manufacturers, consolidating existing practice rather than shifting the balance in either direction.<\/p>\n\n\n\n

Data Protection and Regulatory Linkage<\/strong><\/h2>\n\n\n\n

Chile implemented data exclusivity through its FTA with the United States, which entered into force in 2004, and separately through its FTA with the European Union, which entered into force in 2003. Both FTAs require five years of data protection for new pharmaceutical products. The data exclusivity framework protects undisclosed clinical data from commercial use by generic applicants for five years from the date of marketing authorization in Chile. Unlike some FTA data exclusivity frameworks, Chile’s system has been interpreted to run concurrently with patent protection rather than independently.<\/p>\n\n\n\n

Chile’s patent linkage system, established following the U.S. FTA, requires generic applicants to certify to ANAMED that either the relevant patents have expired, that no relevant patents exist, or that the applicant believes the patent is invalid or will not be infringed by the generic product. This self-certification system places the burden on the generic applicant to make an affirmative representation about patent status, rather than requiring ANAMED to independently check patent registries. Patent holders who believe the self-certification is incorrect can seek damages and injunctions through the courts.<\/p>\n\n\n\n

Chilean courts have developed a body of case law on pharmaceutical patent linkage and data exclusivity that is more settled than in most other South American countries, partly because the FTA obligations have been in place longer. The Court of Appeals of Santiago has heard numerous pharmaceutical patent disputes and has generally applied a balanced standard: strong protection for clearly valid patents, but no automatic extension of protection for questionable claims or procedural linkage manipulation.<\/p>\n\n\n\n

Ecuador, Bolivia, and Venezuela: The TRIPS Flexibility Block<\/strong><\/h1>\n\n\n\n

Ecuador: Compulsory Licensing as Policy<\/strong><\/h2>\n\n\n\n

Ecuador’s pharmaceutical patent system is governed by the Intellectual Property Law (Ley de Propiedad Intelectual, codified in 2016) and CAN Decision 486 for patentability standards. The basic patent term is 20 years from filing, with no extension mechanism and no data exclusivity framework beyond a narrow confidentiality provision for clinical data submitted to ARCSA (Agencia de Regulacion y Control Sanitario), Ecuador’s health authority. Ecuador has explicitly declined to implement TRIPS-plus data exclusivity, citing public health concerns, and no FTA between Ecuador and the United States or European Union is in force.<\/p>\n\n\n\n

Ecuador issued a compulsory license on lopinavir\/ritonavir (Abbott’s Kaletra) in April 2010, making it one of the few South American countries to have issued a formal compulsory license on an HIV drug after Brazil. The 2010 license authorized the importation of generic lopinavir\/ritonavir from Indian manufacturer Cipla for use in Ecuador’s national HIV\/AIDS program. The license cited national emergency provisions under CAN Decision 486 Article 65 and the Doha Declaration. Abbott ultimately negotiated a tiered pricing agreement with Ecuador that reduced the effective price differential with the generic, but the license remained formally in force [12].<\/p>\n\n\n\n

Ecuador has maintained an active stance on pharmaceutical patent policy under successive governments across the political spectrum. The government’s 2014 National Development Plan explicitly identified compulsory licensing as a public health tool and directed health authorities to monitor pharmaceutical patent expiry dates and initiate generic procurement processes in advance of patent expiry. This institutional approach to patent expiry monitoring reflects a level of pharmaceutical patent sophistication that is unusual for a smaller South American economy.<\/p>\n\n\n\n

Bolivia: Minimal Patent Infrastructure, Maximum TRIPS Flexibility<\/strong><\/h2>\n\n\n\n

Bolivia’s pharmaceutical patent system is among the least developed in South America. The Intellectual Property Law (Law 1322 of 1992) and CAN Decision 486 provide the legal framework, but SENAPI (Servicio Nacional de Propiedad Intelectual) has limited examiner capacity and the pharmaceutical patent examination process is slow and inconsistent. Average examination times for pharmaceutical applications at SENAPI exceed 6 years, and the backlog is substantial relative to office capacity.<\/p>\n\n\n\n

Bolivia has never enacted data exclusivity legislation. The constitutional provisions adopted under President Morales’ government in 2009 treated access to essential medicines as a constitutional right and explicitly authorized the state to use TRIPS flexibilities, including compulsory licensing, to ensure access. Bolivia invoked CAN Decision 486’s compulsory licensing provisions in 2012 to secure access to antiretroviral drugs for its national HIV program. The practical effect of Bolivia’s approach is that pharmaceutical companies operating in Bolivia face a 20-year patent term with no extensions, no data exclusivity, and a demonstrated willingness to use compulsory licensing for essential medicines.<\/p>\n\n\n\n

For global pharmaceutical companies, Bolivia is a small market (population approximately 12 million, annual pharmaceutical market under $1 billion) whose patent risk does not justify extensive legal strategy. Most major brand pharmaceutical companies file patents in Bolivia as part of regional portfolio maintenance but do not rely on Bolivian patent exclusivity for any significant component of their global revenue model. Generic manufacturers are active in Bolivia, and the market is predominantly served by generics, particularly for essential medicines.<\/p>\n\n\n\n

Venezuela: Patent Law Under Economic Collapse<\/strong><\/h2>\n\n\n\n

Venezuela’s pharmaceutical patent system is governed by the Intellectual Property Law (Ley de Propiedad Industrial, updated in 2001) and, until Venezuela’s withdrawal from the Andean Community in 2006, CAN Decision 486. Venezuela left the CAN in 2006 under President Chavez, citing incompatibility with its development model, and subsequently joined Mercosur in 2012 before being suspended in 2016 for non-compliance with democratic governance standards. Venezuela’s IP framework now operates entirely under domestic law without a regional framework.<\/p>\n\n\n\n

The practical significance of Venezuelan pharmaceutical patent protection has been substantially reduced by the country’s economic collapse, hyperinflation, and import restrictions. Pharmaceutical companies have faced extreme difficulties importing drugs into Venezuela due to foreign exchange controls and payment risks. The parallel collapse of the public health system has made patent enforcement largely theoretical: Venezuela’s public health authorities lack the administrative capacity to enforce patent linkage or data exclusivity even if the laws required it. Generic drugs, compounding pharmacies, and informal importation channels dominate the Venezuelan pharmaceutical market.<\/p>\n\n\n\n

For patent strategy purposes, Venezuela is typically treated as a low-priority jurisdiction for pharmaceutical companies, with filing decisions based on regional portfolio completeness rather than commercial exclusivity analysis. The 20-year patent term from filing applies in principle, but the effective market environment makes patent protection largely academic in the current context.<\/p>\n\n\n\n

Paraguay and Uruguay: Small Markets, Different Priorities<\/strong><\/h1>\n\n\n\n

Paraguay: Limited Examination, Limited Market<\/strong><\/h2>\n\n\n\n

Paraguay’s pharmaceutical patent system operates under Law 1630\/2000 on Patents of Invention and Law 868\/81 on industrial property. The basic patent term is 20 years from filing for pharmaceutical products. The national industrial property office, DINAPI (Direcci\u00f3n Nacional de Propiedad Intelectual), has limited examiner capacity and average examination times of 5 to 8 years for pharmaceutical applications. Paraguay has a limited data exclusivity framework under Ministry of Health regulations that provides 5 years of protection for clinical data, but enforcement is inconsistent.<\/p>\n\n\n\n

Paraguay’s pharmaceutical market is small (population approximately 7 million, annual pharmaceutical market under $700 million) and is significantly affected by informal cross-border trade with Brazil and Argentina. The price differential between branded drugs in Paraguay and generic equivalents available across the border is a persistent public health issue, and Paraguayan health authorities have limited capacity to maintain patent registries or enforce linkage mechanisms. For practical purposes, Paraguay offers pharmaceutical patent protection in name but limited enforcement capacity in practice.<\/p>\n\n\n\n

Uruguay: The Mercosur Member With Stronger Institutions<\/strong><\/h2>\n\n\n\n

Uruguay presents a more developed pharmaceutical patent environment than Paraguay despite its smaller population (approximately 3.5 million). Uruguay’s patent law (Law 17.164 of 1999) provides a 20-year patent term from filing and includes a relatively well-functioning patent examination process at the National Directorate of Industrial Property (DNPI). Uruguay’s regulatory authority, the Ministry of Public Health (MSP), applies a data exclusivity framework of 5 years for new chemical entities, though generic applicants may obtain approval through independent bioequivalence studies without reference to protected data.<\/p>\n\n\n\n

Uruguay is a member of Mercosur, the South American trade bloc that includes Brazil, Argentina, and Paraguay. Mercosur has not achieved the same level of IP harmonization as the CAN, and there is no Mercosur equivalent to CAN Decision 486 setting uniform patentability standards. Each Mercosur member maintains its own patent examination standards, creating a fragmented regional landscape for pharmaceutical patent holders seeking predictable exclusivity across the bloc.<\/p>\n\n\n\n

Uruguay’s pharmaceutical market, while small, has attracted attention as a policy innovation laboratory. Uruguay was the first country in Latin America to implement plain packaging for tobacco products, demonstrating a willingness to apply public health policy tools that override commercial IP interests. This policy context, combined with its Mercosur membership and functional regulatory institutions, makes Uruguay a more complex pharmaceutical IP jurisdiction than its size alone would suggest.<\/p>\n\n\n\n

CAN Decision 486: The Regional Baseline That Prevents Evergreening<\/strong><\/h1>\n\n\n\n

Patentability Standards Under Decision 486<\/strong><\/h2>\n\n\n\n

CAN Decision 486, adopted by the Andean Community in September 2000, is the most significant regional pharmaceutical patent framework in South America. It directly governs the patent systems of Colombia, Peru, Ecuador, and Bolivia, covering a combined population of approximately 120 million people and combined pharmaceutical markets of approximately $15 billion annually. The Decision’s patentability standards are where it has the most concrete impact on pharmaceutical exclusivity duration [13].<\/p>\n\n\n\n

Article 21 of Decision 486 defines what is not considered an invention for patent purposes. The list includes biological and genetic material existing in nature, scientific discoveries, mathematical methods, financial schemes, and therapeutic or diagnostic methods for treating humans or animals. More relevant to pharmaceutical patent strategy, Article 15 defines the conditions of novelty, inventive step, and industrial applicability, while Articles 20 and 21 create specific exclusions that directly affect common pharmaceutical patent strategies.<\/p>\n\n\n\n

Article 20(c) of Decision 486 excludes from patentability any product whose claimed subject matter was already patented or disclosed prior to the patent application. This provision is applied strictly by CAN patent offices to block “secondary” patents on new forms of known compounds. Article 20(d) provides that second uses of known compounds are not patentable, meaning that if aspirin is already patented for pain relief, a new patent on aspirin for cardiovascular prevention would not be grantable in CAN member states. This provision directly blocks one of the most common evergreening strategies used in high-income country patent systems.<\/p>\n\n\n\n

How CAN Decision 486 Compares to TRIPS<\/strong><\/h2>\n\n\n\n

TRIPS does not explicitly prohibit secondary patents on new forms of known compounds or new uses. Article 27 of TRIPS requires that patents be available for inventions in all fields of technology that are new, involve an inventive step, and are capable of industrial application. Whether a polymorph of a known drug or a new use of a known compound meets these criteria is left to national patent law interpretation. Countries like the United States and European Patent Office member states have generally allowed such patents; CAN member states have generally refused them.<\/p>\n\n\n\n

The TRIPS compatibility of Decision 486’s restrictive patentability standards was tested in the Novartis AG v. Union of India case, which was decided by the Indian Supreme Court in 2013 and applied India’s own restrictive Section 3(d) standard to imatinib. Although this was an Indian case, the legal arguments were closely followed in CAN countries, and the Indian court’s reasoning, which held that TRIPS Article 27 allows national variation in inventive step standards, reinforced the legal justification for Decision 486’s approach [14]. CAN member states have cited the Indian Supreme Court decision and related scholarship in defending Decision 486 against trade pressure.<\/p>\n\n\n\n

The Inventive Step Standard in CAN Countries<\/strong><\/h3>\n\n\n\n

The inventive step standard under Decision 486 requires that the invention is not “obvious to a person skilled in the art” at the time of filing. CAN patent offices generally apply this standard in a way that is more demanding than U.S. or European offices for pharmaceutical claims. The CAN Secretariat has issued technical guides confirming that the inventive step assessment must consider what was known in the specific therapeutic area at the filing date, including prior art from academic publications, clinical trial results, and patent disclosures in other jurisdictions.<\/p>\n\n\n\n

The practical effect is that many pharmaceutical patents that would be granted in the United States, Europe, or Japan are refused in CAN member states on inventive step grounds. A formulation patent for a known drug in a new delivery system, for example, might be grantable in the United States if it produces unexpected efficacy improvements, but would face significant inventive step challenges in Colombia or Ecuador absent very strong efficacy data demonstrating a non-obvious improvement over the prior art.<\/p>\n\n\n\n

Summary: Patent Duration and Key Mechanisms by Country<\/strong><\/h2>\n\n\n\n
Country<\/strong><\/th>Basic Term<\/strong><\/th>PTE\/Ext.<\/strong><\/th>Data Excl.<\/strong><\/th>Patent Linkage<\/strong><\/th>CAN Member<\/strong><\/th><\/tr><\/thead>
Brazil<\/td>20 yrs (filing)<\/td>None (2021 reform limited)<\/td>10 yrs (pharma)<\/td>No<\/td>No<\/td><\/tr>
Argentina<\/td>20 yrs (filing)<\/td>None<\/td>5 yrs (limited)<\/td>No<\/td>No<\/td><\/tr>
Colombia<\/td>20 yrs (filing)<\/td>Limited linkage-based<\/td>5 yrs<\/td>Yes (modified)<\/td>Yes<\/td><\/tr>
Peru<\/td>20 yrs (filing)<\/td>Restoration possible (FTA)<\/td>5 yrs (data prot.)<\/td>Yes (FTA-driven)<\/td>Yes<\/td><\/tr>
Chile<\/td>20 yrs (filing)<\/td>None formally<\/td>5 yrs<\/td>Yes (since 2011)<\/td>No<\/td><\/tr>
Ecuador<\/td>20 yrs (filing)<\/td>None<\/td>5 yrs (limited)<\/td>No<\/td>Yes<\/td><\/tr>
Bolivia<\/td>20 yrs (filing)<\/td>None<\/td>Not enacted<\/td>No<\/td>Yes<\/td><\/tr>
Venezuela<\/td>20 yrs (filing)<\/td>None<\/td>Not enacted<\/td>No<\/td>Former (left 2006)<\/td><\/tr>
Paraguay<\/td>20 yrs (filing)<\/td>None<\/td>5 yrs (limited)<\/td>No<\/td>No<\/td><\/tr>
Uruguay<\/td>20 yrs (filing)<\/td>None<\/td>5 yrs<\/td>No<\/td>No<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Note: “PTE\/Ext.” refers to any mechanism extending protection beyond 20 years from filing. “Data Excl.” periods are from first domestic marketing authorization. Sources: national patent office data, CAN Secretariat, WIPO IP Statistics, DrugPatentWatch [1].<\/em><\/p>\n\n\n\n

Compulsory Licensing Across the Region: When Governments Override Patents<\/strong><\/h1>\n\n\n\n

The Legal Framework: TRIPS, Doha, and National Implementation<\/strong><\/h2>\n\n\n\n

Every South American country has incorporated compulsory licensing provisions into its national patent law, as required by TRIPS Article 31. The specific grounds and procedures differ across countries, but all systems permit compulsory licensing for national emergency, extreme urgency, or public non-commercial use. The Doha Declaration of 2001 clarified that countries are free to determine what constitutes a national emergency or extreme urgency, giving governments broad discretion to invoke compulsory licensing for public health reasons.<\/p>\n\n\n\n

The practical barriers to compulsory licensing have historically included diplomatic pressure from the United States and the European Union, the administrative complexity of issuing and implementing a compulsory license, and the potential deterrent effect on future pharmaceutical investment in the issuing country. Brazil’s 2007 efavirenz license demonstrated that a major emerging economy could issue a compulsory license without facing formal WTO dispute settlement or significant trade retaliation. That precedent removed some of the diplomatic deterrence, particularly for drugs in the antiretroviral, oncology, and hepatitis treatment categories where public health arguments are strongest.<\/p>\n\n\n\n

The Record: South American Compulsory Licenses and Threats<\/strong><\/h2>\n\n\n\n
Country<\/strong><\/th>Drug<\/strong><\/th>Year<\/strong><\/th>Patentee<\/strong><\/th>Outcome<\/strong><\/th><\/tr><\/thead>
Brazil<\/td>Efavirenz (Stocrin)<\/td>2007<\/td>Merck<\/td>CL issued; generic imported from India<\/td><\/tr>
Brazil<\/td>Sofosbuvir (Sovaldi)<\/td>2018-19<\/td>Gilead<\/td>Threatened; Gilead reduced price<\/td><\/tr>
Ecuador<\/td>Lopinavir\/Ritonavir (Kaletra)<\/td>2010<\/td>Abbott<\/td>CL issued; generic imported<\/td><\/tr>
Colombia<\/td>Imatinib (Gleevec)<\/td>2016<\/td>Novartis<\/td>CL declared; Novartis challenged<\/td><\/tr>
Colombia<\/td>Sofosbuvir (Sovaldi)<\/td>2016<\/td>Gilead<\/td>Public interest declaration; price cut<\/td><\/tr>
Bolivia<\/td>Multiple ARVs<\/td>2012<\/td>Various<\/td>CL framework invoked; HIV programme<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Sources: WHO, MSF Access Campaign, WTO notifications, academic literature, company statements [5, 12, 15].<\/em><\/p>\n\n\n\n

Price Negotiation as the Alternative to Formal Licensing<\/strong><\/h3>\n\n\n\n

The data in the table above understates the frequency and commercial impact of compulsory license threats, because the most common outcome of a credible threat is a negotiated price reduction rather than a formal license. Pharmaceutical companies generally prefer to negotiate price reductions over having their manufacturing processes examined and their data packages referenced in government-authorized generic production. Price negotiations triggered by compulsory license threats have generated cost savings in the hundreds of millions of dollars across South American health systems for drugs including sofosbuvir, bedaquiline, pembrolizumab, and several antiretrovirals.<\/p>\n\n\n\n

From the patent strategy perspective, companies operating in South America must treat the compulsory license risk as a genuine component of their pricing and exclusivity model, not a theoretical risk that public relations management can neutralize. The Brazilian, Ecuadorian, and Colombian precedents have created institutional knowledge across South American health ministries and civil society organizations on how to prepare and present a compulsory license request. The technical expertise required to draft a legally defensible compulsory license application now exists in multiple South American countries, reducing the practical barriers to issuance.<\/p>\n\n\n\n

“In Latin America, the threat of compulsory licensing has achieved price reductions of 40 to 70 percent for several patented medicines, without a formal license being issued in most cases — making the threat itself the most effective pricing tool available to health ministries.”<\/em>
— MSF Access Campaign, Untangling the Web of Antiretroviral Price Reductions, 2022 [15]<\/em><\/p>\n\n\n\n

Patent Office Backlogs: The Hidden Distortion in Effective Patent Life<\/strong><\/h1>\n\n\n\n

How Examination Delays Affect Real Exclusivity<\/strong><\/h2>\n\n\n\n

A nominally 20-year patent term from filing is not the same as 20 years of commercial exclusivity when the patent office takes a decade to issue the patent. Understanding this distinction is critical for pharmaceutical patent strategy in South America, where examination backlogs are among the most severe in the world. The table below summarizes examination times and backlog status across the major South American patent offices.<\/p>\n\n\n\n

Country<\/strong><\/th>Patent Office<\/strong><\/th>Avg. Examination Time<\/strong><\/th>Backlog Status (2023)<\/strong><\/th><\/tr><\/thead>
Brazil<\/td>INPI-BR<\/td>7-11 years (pharma)<\/td>Critical; reform ongoing<\/td><\/tr>
Argentina<\/td>INPI-AR<\/td>8-12 years (pharma)<\/td>Severe; 60,000+ pending<\/td><\/tr>
Colombia<\/td>SIC<\/td>4-6 years<\/td>Moderate; improving<\/td><\/tr>
Peru<\/td>INDECOPI<\/td>4-7 years<\/td>Moderate<\/td><\/tr>
Chile<\/td>INAPI<\/td>3-5 years<\/td>Manageable<\/td><\/tr>
Ecuador<\/td>SENADI<\/td>3-6 years<\/td>Moderate<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Sources: WIPO IP Statistics Database 2023, INPI-BR Annual Report, INPI-AR, SIC, INDECOPI, INAPI official data. DrugPatentWatch tracks patent grant dates alongside filing dates to calculate effective exclusivity periods for covered products [1].<\/em><\/p>\n\n\n\n

The Backlog Problem in Brazil and Argentina<\/strong><\/h2>\n\n\n\n

The examination backlogs at INPI-BR and INPI-AR represent a systemic distortion in the South American pharmaceutical patent landscape. For INPI-BR, the consequences of the backlog were partially addressed by the STF’s 2021 decision striking down the minimum-term rule, but the underlying problem of slow examination remains. INPI-BR processed approximately 18,000 pharmaceutical patent applications in the 2022-2023 period as part of a backlog reduction effort, but the pending queue continues to include applications filed in the mid-2010s.<\/p>\n\n\n\n

The INPI-AR situation is more severe. The Argentine government has periodically announced backlog reduction initiatives, but structural underfunding and high examiner turnover rates have prevented sustained progress. For pharmaceutical companies, the INPI-AR backlog creates practical problems beyond the obvious uncertainty about patent status. Argentine patent attorneys advising foreign companies must assess whether a pending application provides any practical market exclusivity during the period before grant, and whether the competitive risk of disclosure (which occurs upon publication 18 months after filing) outweighs the eventual exclusivity benefit of a granted patent.<\/p>\n\n\n\n

Strategic Responses to Backlog Uncertainty<\/strong><\/h2>\n\n\n\n

Pharmaceutical companies have developed several approaches to managing backlog uncertainty in South America. First, priority filing strategies: companies file PCT applications and request early national phase entry in South American countries to start the examination clock as early as possible. Second, divisional application strategies: filing multiple divisional applications with different claim sets can extend the period of uncertainty that generic manufacturers face, since each application has its own examination queue position. Third, supplementary protection through data exclusivity: in countries with functioning data exclusivity frameworks, companies rely on data exclusivity to provide a period of certain protection while awaiting patent examination outcomes.<\/p>\n\n\n\n

Generic manufacturers have adapted their own strategies. Many Argentine, Brazilian, and Colombian generic companies maintain legal departments that track pending pharmaceutical applications at national patent offices, identify applications at high risk of grant, and prepare to challenge applications in post-grant opposition proceedings as soon as patents are issued. Some generic companies file comments during the examination process in countries that permit third-party observations, citing prior art that may limit or prevent grant. The DrugPatentWatch platform’s coverage of South American pending applications and patent publications provides generic manufacturers with systematic monitoring capabilities that were previously available only to companies with large in-house legal teams [1].<\/p>\n\n\n\n

Patent Intelligence in South America: Data, Tools, and Decision-Making<\/strong><\/h1>\n\n\n\n

The Information Gap and Why It Matters<\/strong><\/h2>\n\n\n\n

Pharmaceutical patent strategy in South America has historically suffered from an information gap that does not exist in the U.S. or European markets. The FDA’s Orange Book and the European Patent Office’s public databases provide consolidated, searchable access to pharmaceutical patent data. South American countries generally lack equivalent consolidated resources: patent office databases are often incomplete, drug regulatory databases do not always interface with patent registries, and regional databases integrating multi-country coverage have been slow to develop.<\/p>\n\n\n\n

This information gap has had asymmetric effects. Large multinational pharmaceutical companies have maintained in-country patent counsel networks that provide local patent data through professional relationships with patent offices and regulatory authorities. Generic manufacturers, particularly domestic South American generics, have often operated with incomplete patent information, leading to both missed patent challenge opportunities and, in some cases, unintentional patent infringement.<\/p>\n\n\n\n

How DrugPatentWatch Covers South American Markets<\/strong><\/h2>\n\n\n\n

DrugPatentWatch has expanded its Latin American patent coverage substantially in recent years, providing consolidated access to pharmaceutical patent data from Brazilian INPI, Colombian SIC, Chilean INAPI, and Peruvian INDECOPI, as well as selected data from other South American patent offices. The platform aggregates patent filing dates, publication dates, grant dates, opposition proceedings, and expiry dates alongside drug product information from national regulatory databases, creating a searchable cross-reference between patents and marketed drug products for the South American context [1].<\/p>\n\n\n\n

For pharmaceutical companies assessing the competitive landscape in South American markets, the value of consolidated patent intelligence is concrete. A company evaluating generic entry timing in Brazil can use DrugPatentWatch to track the examination status of pending applications, identify relevant Orange Book-equivalent listings from ANVISA’s registration database, and cross-reference Brazilian patent data with U.S. PTE and European SPC data to build a complete picture of the innovator’s global exclusivity strategy. For investors modeling the revenue runway of a Brazilian generic company’s product pipeline, the platform provides the patent expiry data that underlies revenue forecasting.<\/p>\n\n\n\n

Payers and health ministries are also using pharmaceutical patent intelligence tools. Brazil’s Ministry of Health, Colombia’s INVIMA, and Chile’s ANAMED have all cited patent expiry data in their pharmaceutical procurement and pricing policy decisions. When a health ministry is negotiating the price of a patented drug with 24 months remaining until patent expiry in the domestic market, it is negotiating with detailed knowledge of the exclusivity timeline. That knowledge shifts the balance of the negotiation in ways that were not possible when patent expiry information was difficult to access and aggregate.<\/p>\n\n\n\n

Investment and M&A in South America: Reading the Patent Map<\/strong><\/h1>\n\n\n\n

The Generic Company Acquisition Calculus<\/strong><\/h2>\n\n\n\n

South American generic pharmaceutical companies represent attractive M&A targets for multinational generic manufacturers precisely because the South American patent landscape creates predictable entry opportunities. A generic company with a portfolio of products already positioned for market entry upon patent expiry in Brazil, Argentina, and Colombia represents a set of near-term revenue opportunities that can be valued against the relevant patent expiry timelines. The accuracy of that valuation depends directly on the quality of the patent expiry data underlying the model.<\/p>\n\n\n\n

Teva’s historical acquisitions of South American generic companies, including its acquisition of Rimsa in Mexico and its various Brazilian generic assets, reflect this logic. Viatris (formed from the merger of Mylan and Pfizer’s Upjohn division) has been active in the Brazilian generic market, as has Sun Pharmaceutical Industries following its acquisition of Ranbaxy. In each case, the value proposition centered on a portfolio of generics positioned against the South American patent cliff for specific brand products, with patent expiry timing as the critical variable.<\/p>\n\n\n\n

The Brazilian market receives the most attention because of its scale ($29 billion annually) and because the STF’s 2021 decision accelerated the effective patent expiry of hundreds of products that had been protected by minimum-term extensions. The wave of generic entrants that followed the STF decision represents exactly the kind of patent cliff that generic company M&A models anticipate and try to position for. Companies that had built portfolios around these expiry dates benefited substantially from accurate patent intelligence in the 2020 to 2024 period [16].<\/p>\n\n\n\n

Brand Company Exclusivity Strategies in the Region<\/strong><\/h2>\n\n\n\n

Brand pharmaceutical companies operating in South America face a different optimization problem than they face in the U.S. or Europe. There are no PTEs or SPCs to extend the basic 20-year term. There are no pediatric exclusivity add-ons. Data exclusivity provides limited incremental protection over patent life in most markets. The result is that brand companies’ exclusivity strategies in South America focus on maximizing protection within the 20-year term: filing patents early in the development process to maximize the commercial exclusivity period within the term, constructing patent portfolios broad enough to require generic manufacturers to challenge multiple patents rather than one, and maintaining patent litigation capabilities in Brazil, Argentina, and Colombia where the financial stakes justify legal investment.<\/p>\n\n\n\n

The CAN Decision 486 prohibition on secondary patents substantially constrains portfolio construction strategies in Colombia, Peru, Ecuador, and Bolivia. Brand companies cannot build the kind of layered formulation-device-method patent portfolios in CAN countries that they build in the United States. The result is that CAN market exclusivity is more binary: the compound patent provides protection for roughly 20 years from filing, and when it expires, generics enter without the stepped barrier that multiple overlapping patents would create in a less restrictive system.<\/p>\n\n\n\n

Pricing Strategy and the Patent Clock<\/strong><\/h3>\n\n\n\n

The combination of shorter effective exclusivity periods (due to examination backlogs reducing the commercial exploitation window within the 20-year term), restrictions on secondary patents, and active compulsory license threats has produced a specific pricing dynamic in South American pharmaceutical markets. Brand companies typically launch at prices significantly higher than local generic alternatives, knowing they must recover R&D investment within a defined exclusivity window, but face more rapid price negotiation and regulatory scrutiny than in high-income markets.<\/p>\n\n\n\n

Value-based pricing, tiered pricing by income level, and patent pool agreements have all been used in South America as alternatives to maximizing price within the exclusivity window. The Medicines Patent Pool has negotiated voluntary licenses covering several South American countries for HIV, hepatitis C, and tuberculosis drugs. These arrangements effectively reduce the exclusivity value of the relevant patents in covered markets, but they provide pharmaceutical companies with an alternative to compulsory license risk and the reputational costs of being seen as a barrier to essential medicine access.<\/p>\n\n\n\n

The 2025-2030 Expiration Landscape: What Loses Protection and When<\/strong><\/h1>\n\n\n\n

Drugs Facing Patent Expiry in South American Markets<\/strong><\/h2>\n\n\n\n

The period from 2025 to 2030 will bring significant pharmaceutical patent expirations across South American markets, creating entry opportunities for domestic and international generic manufacturers. The specific timing of expiry in each South American country differs from the U.S. and European timelines because filing dates vary, examination grants occurred at different times, and data exclusivity periods have different start dates. Understanding these country-specific timelines requires access to the kind of consolidated patent intelligence that DrugPatentWatch provides.<\/p>\n\n\n\n

Several immunology and oncology drugs face compound patent expiry in Brazilian INPI records between 2025 and 2027, including several biologics whose corresponding U.S. patents are still under PTE protection. Because Brazil has no PTE or SPC system, the Brazilian patent expiry can precede the U.S. PTE-extended expiry by 3 to 5 years for drugs where the U.S. patent received a maximal term restoration. This creates a scenario where biosimilar competition begins in Brazil while the innovator still has protected status in the United States, making Brazil simultaneously a generic entry opportunity and a pricing pressure test case for global brand manufacturers.<\/p>\n\n\n\n

In the oncology segment specifically, several checkpoint inhibitor antibodies (PD-1 and PD-L1 pathway inhibitors) that have become standard of care have patent portfolios in South America that are more limited than their U.S. or European equivalents, because CAN member states refused several secondary method-of-treatment patents that were granted in high-income markets. The result is that biosimilar and generic oncology manufacturers are planning earlier market entry in Colombia, Peru, and Ecuador than in comparable European markets.<\/p>\n\n\n\n

The Biosimilar Entry Challenge in South America<\/strong><\/h2>\n\n\n\n

Biosimilar regulatory pathways in South America are less developed than in the United States, Europe, or even India. Brazil’s ANVISA has approved biosimilars for several biologics, including adalimumab biosimilars that entered the Brazilian market before U.S. biosimilars due to the absence of a BPCIA-equivalent patent dance. ANVISA’s biosimilar approval pathway requires clinical comparability data but has a functional review process. Argentina’s ANMAT has a biosimilar pathway that has processed fewer applications, reflecting both the smaller market and the higher uncertainty around patent status during INPI-AR’s examination backlog.<\/p>\n\n\n\n

The challenge for biosimilar manufacturers in South America is not primarily regulatory or patent-based: it is manufacturing and commercial. Biological manufacturing at regulatory standard quality is expensive, and the South American market sizes, while significant in aggregate, may not justify the capital investment in local biosimilar production for most products. The most commercially successful biosimilar entries in South America have been achieved by Indian manufacturers (particularly Dr. Reddy’s, Cipla, and Biocon), who can amortize manufacturing investment across global biosimilar strategies and price competitively in South America as a lower-margin market [17].<\/p>\n\n\n\n

GLP-1 Drugs and the South American Exclusivity Question<\/strong><\/h2>\n\n\n\n

Semaglutide (Ozempic\/Wegovy) and tirzepatide (Mounjaro\/Zepbound) represent the most commercially significant patent expiry questions in the South American pharmaceutical market for the second half of the 2020s. Novo Nordisk’s semaglutide compound patent was filed in the early 2000s, and its South American national phase entries were filed through the PCT system. The compound patent expires in South American markets in approximately 2026, consistent with the global expiry timeline, though Brazilian and Argentine examination delays may mean some patent instruments expire slightly later due to late grants.<\/p>\n\n\n\n

Unlike the United States, where Novo Nordisk may obtain PTE protection extending semaglutide exclusivity to 2031 or beyond, South American markets have no extension mechanism. Compound patent expiry in South America in 2026 means generic manufacturers can legally enter those markets in 2026, provided they meet regulatory and bioequivalence requirements. Several South American manufacturers, particularly Brazilian generic companies like EMS and Eurofarma and Argentine generics, have already filed drug master files and begun bioequivalence study preparations in anticipation of the semaglutide patent expiry. The commercial opportunity is significant: semaglutide’s South American revenues are currently in the hundreds of millions of dollars annually and growing rapidly as obesity treatment awareness expands.<\/p>\n\n\n\n

Practical Guidance: Navigating the South American Patent System<\/strong><\/h1>\n\n\n\n

Filing Strategy: Timing, Coverage, and Claim Design for South America<\/strong><\/h2>\n\n\n\n

Pharmaceutical companies with new drug candidates should treat South American filing strategy as a distinct analytical exercise from U.S. or European filing strategy. The key differences that drive distinct decisions are: the absence of PTE or SPC mechanisms means the filing date is the only starting point for the 20-year clock, making early national phase entry critical; CAN Decision 486 restrictions on secondary patents mean claim portfolios must be designed around the compound patent from the outset rather than supplemented later; and examination backlogs mean that the commercial exploitation window within the 20-year term may be as short as 8 to 12 years in Brazil and Argentina.<\/p>\n\n\n\n

The practical implication is that for CAN member state markets, a strong compound patent filed early in development is worth far more than a cluster of secondary patents filed later. Claim drafting for CAN markets should be broader at the compound level and should anticipate the Article 20 exclusions by ensuring the compound claims are not drafted in ways that depend on form, salt, or use limitations that CAN patent offices will refuse. For Brazilian and Argentine markets, filing as early as PCT priority allows and monitoring examination progress closely allows companies to manage the backlog-related uncertainty more actively.<\/p>\n\n\n\n

Compulsory License Risk Management<\/strong><\/h2>\n\n\n\n

Companies that have drugs on the World Health Organization’s Model List of Essential Medicines and that are priced at levels generating compulsory license discussion in South American health ministries should conduct formal compulsory license risk assessments as part of their regional pricing strategy. This assessment should identify the specific legal pathway for a compulsory license in each of the five highest-risk countries (Brazil, Colombia, Ecuador, Bolivia, and Peru), quantify the revenue impact of a formal license at Indian generic prices, and model the price point at which the government’s cost-effectiveness analysis would not support a compulsory license proceeding.<\/p>\n\n\n\n

Voluntary licensing and tiered pricing programs, offered proactively before a compulsory license threat materializes, have generally produced better commercial outcomes than waiting for the threat and then negotiating under pressure. The Medicines Patent Pool agreements on HIV and hepatitis C drugs demonstrate that voluntary licensing can be structured to maintain revenue from high-income markets while reducing the compulsory license risk in South American markets. The key is that the license terms must be sufficiently attractive to satisfy the health ministry’s cost-effectiveness calculation, which requires accurate intelligence about what generic prices would be absent a license.<\/p>\n\n\n\n

Generic Entry Planning Across South American Markets<\/strong><\/h2>\n\n\n\n

Generic pharmaceutical companies planning South American market entry should build country-specific patent expiry timelines that account for examination timing differences, pending application risks, and data exclusivity periods separately from patent protection. A drug whose U.S. patent expired in 2020 may still have a pending application at INPI-BR that could be granted at any time, or may have already passed through examination with a specific Brazilian grant date that differs from the U.S. expiry. These differences are not visible from U.S. patent data alone.<\/p>\n\n\n\n

Monitoring platforms like DrugPatentWatch that cover South American patent offices provide generic companies with the multi-jurisdiction patent intelligence needed to plan market entry without depending on country-specific patent counsel relationships in every jurisdiction. For companies building South American product pipelines, the combination of U.S. patent expiry data, South American pending application monitoring, and country-specific data exclusivity timelines creates a complete market entry opportunity model. The companies that systematically build and maintain these models will consistently identify market entry windows that competitors relying on manual intelligence miss [1].<\/p>\n\n\n\n

Health Ministry Engagement: The Overlooked Competitive Lever<\/strong><\/h2>\n\n\n\n

Generic manufacturers and innovator companies alike can benefit from engaging directly with South American health ministries on pharmaceutical patent policy. Ministries of health in Brazil, Colombia, Peru, and Chile have technical teams that monitor patent expiry dates, track compulsory license precedents, and participate in WHO and PAHO policy discussions. Companies that provide accurate, accessible patent information to these ministries, whether as part of voluntary licensing negotiations, pricing discussions, or simple regulatory engagement, are better positioned to manage the policy environment around their products.<\/p>\n\n\n\n

For generic companies, engaging health ministries before patent expiry allows for pre-qualification of generic products within national health system procurement processes, ensuring that the first day of legal market entry translates into rapid actual market penetration. Brazil’s RENAME (National List of Essential Medicines) procurement process, Colombia’s SISMED price monitoring system, and Chile’s ISP procurement channels all provide pathways for generic manufacturers to position products for immediate uptake upon patent expiry, but these pathways require advance engagement that cannot be initiated at the last minute.<\/p>\n\n\n\n

Key Takeaways<\/strong><\/h1>\n\n\n\n

\u2022  Every South American country provides a 20-year pharmaceutical patent term from filing, consistent with TRIPS. No South American country has a patent term extension (PTE) or supplementary protection certificate (SPC) system equivalent to the U.S. or EU, making the filing date the only determinant of the maximum 20-year protection window.<\/p>\n\n\n\n

\u2022  Four countries — Colombia, Peru, Ecuador, and Bolivia — are governed by CAN Decision 486, which prohibits secondary patents on new forms of known compounds and new uses of known active ingredients. This prohibition directly prevents the evergreening strategies that extend effective exclusivity in the United States, Europe, and Japan.<\/p>\n\n\n\n

\u2022  Brazil and Argentina have the most severe patent office backlogs in South America, with average pharmaceutical examination times of 7 to 12 years from filing. This reduces the effective commercial exclusivity period within the 20-year term and creates uncertainty for both brand and generic companies that systematic patent monitoring through platforms like DrugPatentWatch helps to manage.<\/p>\n\n\n\n

\u2022  Brazil’s 2021 STF decision striking down the minimum-term patent extension provision has accelerated effective expiry for approximately 2,700 pharmaceutical patents, creating a compressed wave of generic entry opportunities that continues through the mid-2020s.<\/p>\n\n\n\n

\u2022  Data exclusivity frameworks exist in Colombia, Peru, Chile, and Uruguay (five years from domestic approval) and Brazil (ten years), but absent in Argentina, Bolivia, and Venezuela. Data exclusivity in South America rarely extends protection beyond patent life because it runs concurrently with patent protection in most cases.<\/p>\n\n\n\n

\u2022  Compulsory licensing is a genuine operational risk for pharmaceutical companies with high-cost drugs in South American markets. Brazil, Ecuador, and Colombia have each issued or credibly threatened compulsory licenses, generating price reductions of 40 to 70 percent in affected products. Formal licenses have been issued in Brazil (efavirenz, 2007) and Ecuador (lopinavir\/ritonavir, 2010), and price negotiation has prevented formal licensing in several other cases.<\/p>\n\n\n\n

\u2022  The GLP-1 drug category, led by semaglutide, faces compound patent expiry in South American markets in approximately 2026, approximately 5 years earlier than the PTE-extended U.S. expiry. Several South American generic manufacturers are already preparing for market entry, creating a near-term generic competition dynamic in Brazil and Argentina well before the U.S. market faces equivalent pressure.<\/p>\n\n\n\n

\u2022  Generic market entry in South America is faster and more binary than in the U.S. because Brazil lacks patent linkage, CAN markets restrict secondary patents that would otherwise create multi-patent challenges for generic entrants, and the absence of PTE or SPC mechanisms means there is no backstop extension available to brand companies once the compound patent expires.<\/p>\n\n\n\n

FAQ<\/strong><\/h1>\n\n\n\n

1. Can a pharmaceutical company file the same patent application across all South American countries simultaneously?<\/strong><\/h2>\n\n\n\n

Yes, through the Patent Cooperation Treaty (PCT) system. A single PCT application filed at the World Intellectual Property Organization (WIPO) can designate all South American WTO member states. The PCT application establishes the international filing date and provides an international search report and preliminary examination. National phase entry in each South American country must then be initiated within the PCT time limits, typically 30 months from the priority date. Each country then examines the application under its own national standards: Brazil under INPI-BR procedures and Brazilian law, Colombia and Peru under CAN Decision 486 standards, Chile under its own examination guidelines. A patent that would be granted in all these jurisdictions under TRIPS minimum standards may still be refused in CAN countries if it covers a new form or new use of a known compound, demonstrating that PCT filing is a procedural shortcut, not a guarantee of consistent patent outcomes across the region.<\/p>\n\n\n\n

2. If a drug patent expires in Brazil, does that mean generic competition automatically begins the next day?<\/strong><\/h2>\n\n\n\n

Not automatically, but potentially very quickly. Brazil has no patent linkage system, meaning ANVISA approvals are not blocked by patent status. Generic companies that anticipated the expiry would have sought and potentially received ANVISA marketing authorizations before the patent expired. On day one after expiry, a generic company with a pre-approved product can legally sell it. In practice, the speed of generic entry depends on whether the generic company has cleared ANVISA’s regulatory requirements, arranged supply chain logistics, and has commercial distribution infrastructure in place. For major drugs, Brazilian generic companies like EMS, Eurofarma, and Ach\u00e9 typically have products approved and ready to launch within days of patent expiry, with the result that brand drug revenues in Brazil can fall sharply within the first month after expiry, faster than in the U.S. or Europe where the generic approval process itself sometimes takes longer.<\/p>\n\n\n\n

3. How does Argentina’s refusal to grant data exclusivity affect a brand company’s entry strategy?<\/strong><\/h2>\n\n\n\n

The absence of data exclusivity in Argentina means that the only protection a brand company can rely on for commercial exclusivity is patent protection. When the relevant patents expire or are invalidated, generic manufacturers can immediately seek ANMAT marketing authorizations using the publicly available safety and efficacy data from the originator’s registration dossier, without needing to conduct independent clinical trials. This makes the Argentine patent portfolio the sole exclusivity instrument, which in turn makes patent quality particularly important in the Argentine context. A weak patent that might survive in a jurisdiction with data exclusivity backstop protection becomes a critical vulnerability in Argentina, because the data exclusivity safety net that would otherwise prevent immediate generic entry does not exist. Brand companies with strong compound patents and limited secondary patent protection are therefore more exposed to early generic competition in Argentina than in Colombia or Chile.<\/p>\n\n\n\n

4. Is patent term restoration (similar to the U.S. PTE) ever available in South American countries, even informally?<\/strong><\/h2>\n\n\n\n

Formally, no South American country has enacted a patent term restoration system equivalent to the U.S. PTE under 35 U.S.C. Section 156 or the European SPC under EC Regulation 469\/2009. Peru’s FTA with the United States contains a side letter committing Peru to “best efforts” to implement term restoration, but no implementing legislation has been passed as of 2024. Brazil’s minimum-term rule under Article 40 of the 1996 Industrial Property Law served a functionally similar purpose for patents caught in the INPI-BR backlog, by guaranteeing at least 10 years of protection from grant date, but the Brazilian Supreme Court struck down this provision in 2021. In practice, pharmaceutical companies seeking extended protection in South American markets must rely on the 20-year term from filing, early filing strategy, and post-approval data exclusivity where available — there is no formal mechanism for administrative term extension.<\/p>\n\n\n\n

5. How can a pharmaceutical company track patent expiry dates across multiple South American countries efficiently?<\/strong><\/h2>\n\n\n\n

The most efficient approach combines a primary database resource with country-specific legal monitoring. DrugPatentWatch provides consolidated pharmaceutical patent data covering multiple South American jurisdictions, allowing companies to search by active ingredient, brand name, or patent number and retrieve expiry dates, grant dates, and examination status for patents in Brazil, Colombia, Peru, Chile, and selected other South American markets alongside U.S. and European data [1]. For countries not fully covered by international databases, in-country patent counsel relationships remain necessary to monitor pending applications and national patent register changes. The optimal workflow is to use consolidated database resources for systematic monitoring of known drug products and portfolio management, and to engage in-country counsel for specific high-value transactions — product acquisitions, generic launch decisions, or patent challenge proceedings — where the cost of incomplete information is highest.<\/p>\n\n\n\n

References<\/strong><\/h1>\n\n\n\n

[1] DrugPatentWatch. (2024). Pharmaceutical patent expiration and exclusivity database, Latin America coverage. https:\/\/www.drugpatentwatch.com<\/p>\n\n\n\n

[2] World Trade Organization. (2001). Declaration on the TRIPS Agreement and Public Health (Doha Declaration). WT\/MIN(01)\/DEC\/2. https:\/\/www.wto.org\/english\/thewto_e\/minist_e\/min01_e\/mindecl_trips_e.htm<\/p>\n\n\n\n

[3] IQVIA Institute for Human Data Science. (2023). Pharmaco intelligence: Latin America pharmaceutical market report. IQVIA. https:\/\/www.iqvia.com<\/p>\n\n\n\n

[4] Brazil Supreme Federal Tribunal (STF). (2021). Direct Action of Unconstitutionality ADI 5529 (re: Article 40, sole paragraph, Lei 9.279\/1996). STF. https:\/\/portal.stf.jus.br<\/p>\n\n\n\n

[5] Ministry of Health of Brazil. (2007). Decree No. 6.108 of 4 May 2007: Compulsory license of the efavirenz patents for government non-commercial use. Official Gazette of the Federative Republic of Brazil. https:\/\/www.health.gov.br<\/p>\n\n\n\n

[6] Correa, C. M. (2001). Review of the TRIPS Agreement: Fostering the transfer of technology to developing countries. Third World Network. https:\/\/www.twn.my<\/p>\n\n\n\n

[7] World Intellectual Property Organization. (2023). WIPO IP statistics data center: Patent applications and grants by technology, Argentina. WIPO. https:\/\/www3.wipo.int\/ipstats<\/p>\n\n\n\n

[8] Argentina Ministry of Health, Ministry of Agriculture, and INPI-AR. (2012). Joint Resolution 118\/2012: Criteria for the examination of patent applications for pharmaceutical products (the 2012 Patentability Guidelines). Official Gazette of Argentina. https:\/\/www.inpi.gov.ar<\/p>\n\n\n\n

[9] Correa, C. M. (2016). Data exclusivity for pharmaceuticals: An analysis of the argument in favor of TRIPS-plus protection and its implications for developing countries. South Centre Research Paper No. 68. https:\/\/www.southcentre.int<\/p>\n\n\n\n

[10] Garavaglia, C., & Suman, M. (2021). Patent strategies in emerging markets: Evidence from the pharmaceutical sector in Argentina and Brazil. Research Policy, 50(3), 104185. https:\/\/doi.org\/10.1016\/j.respol.2021.104185<\/p>\n\n\n\n

[11] Ministry of Health of Colombia. (2016). Resolution 2475 of May 13, 2016: Public interest declaration for imatinib. MinSalud Colombia. https:\/\/www.minsalud.gov.co<\/p>\n\n\n\n

[12] Ministry of Public Health of Ecuador. (2010). Ministerial Agreement No. 1618: Compulsory license on patents covering lopinavir\/ritonavir. Official Register of Ecuador. https:\/\/www.salud.gob.ec<\/p>\n\n\n\n

[13] Andean Community. (2000). Decision 486: Common Intellectual Property Regime. Andean Community General Secretariat. https:\/\/www.comunidadandina.org<\/p>\n\n\n\n

[14] Supreme Court of India. (2013). Novartis AG v. Union of India, Civil Appeal Nos. 2706-2716 of 2013. Supreme Court of India. https:\/\/www.sci.gov.in<\/p>\n\n\n\n

[15] Medecins Sans Frontieres (MSF). (2022). Untangling the web of antiretroviral price reductions (25th edition). MSF Access Campaign. https:\/\/msfaccess.org<\/p>\n\n\n\n

[16] Brazilian Association of the Generic Drug Industry (Pro Generico). (2023). Annual report: Generic drug market performance in Brazil, 2022-2023. Pro Generico. https:\/\/www.progenericos.org.br<\/p>\n\n\n\n

[17] Ramachandran, G., & Amin, T. (2022). Pharmaceutical patent landscapes in low and middle income countries: Lessons from Brazil, India, and South Africa. Journal of Generic Medicines, 18(2), 67-83. https:\/\/doi.org\/10.1177\/17411343221104129<\/p>\n","protected":false},"excerpt":{"rendered":"

Patent Terms, Data Exclusivity, Compulsory Licensing, and Generic Entry Across 11 Markets Why South America Is the World’s Most Contested […]<\/p>\n","protected":false},"author":1,"featured_media":37319,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-37318","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/37318","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=37318"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/37318\/revisions"}],"predecessor-version":[{"id":37320,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/37318\/revisions\/37320"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/37319"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=37318"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=37318"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=37318"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}